Arcturus Therapeutics Q1 2023 Earnings Report $16.79 -0.22 (-1.29%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Arcturus Therapeutics EPS ResultsActual EPS$0.88Consensus EPS $2.92Beat/MissMissed by -$2.04One Year Ago EPSN/AArcturus Therapeutics Revenue ResultsActual Revenue$80.29 millionExpected Revenue$133.50 millionBeat/MissMissed by -$53.21 millionYoY Revenue GrowthN/AArcturus Therapeutics Announcement DetailsQuarterQ1 2023Date5/9/2023TimeN/AConference Call ResourcesPress ReleaseARCT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Arcturus Therapeutics Earnings HeadlinesArcturus Therapeutics: Anticipated Growth through Innovative Therapies and Strategic TrialsJanuary 17 at 5:40 PM | markets.businessinsider.comArcturus Therapeutics Poised for Transformative Growth in 2025 with Promising Pipeline and Strategic AdvancementsJanuary 17 at 5:49 AM | markets.businessinsider.comStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... This could be the most important building in America.January 19, 2025 | Banyan Hill Publishing (Ad)Arcturus Therapeutics' (ARCT) Buy Rating Reaffirmed at HC WainwrightJanuary 15, 2025 | americanbankingnews.comBuy Rating for Arcturus Therapeutics Driven by Promising Vaccine Candidate and Strategic PartnershipsJanuary 13, 2025 | markets.businessinsider.comArcturus Therapeutics initiates ARCT-2304 studyJanuary 10, 2025 | markets.businessinsider.comSee More Arcturus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcturus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcturus Therapeutics and other key companies, straight to your email. Email Address About Arcturus TherapeuticsArcturus Therapeutics (NASDAQ:ARCT), a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.View Arcturus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
